METHOD FOR DETERMINING BURKHOLDERIA MALLEI CAPSULAR ANTIGEN IMMUNOGENICITY LEVEL Russian patent published in 2007 - IPC G01N33/53 C12Q1/04 

FIELD: medicine.

SUBSTANCE: method involves applying test system comprising nonimmune peritoneal macrophages of guinea pig, avirulent non-capsuliferous B.mallei 10230-11-2 version cells and separate chromatographic antigenic capsule substance fractions of typical encapsulated B.mallei 10230 strain. Phagocytic activity indices give starting criterion for in vitro selecting immunogenic capsular antigen complexes of glanders pathogen with protection function as means for developing specific glanders prophylaxis. Avirulent non-capsuliferous B.mallei 10230-11-2 version cells are selected from typical encapsulated B.mallei 10230 strain by means of hyperimmune antiserum. The cells are introduced into glass flasks containing medium 199 with cattle serum and glass carrying attached nonimmune peritoneal macrophages of guinea pig. Some glanders pathogen antigen capsule fractions are added and test strain phagocytability is dynamically tested during 1-3 h. The phagocytability index value is interpreted in terms of capsular antigen complexes immunostimulation or immunosuppression levels.

EFFECT: high accuracy in estimating immunogenic activity level of some capsular glanders pathogen antigens.

1 dwg, 1 tbl